Ikena Oncology - IMA EV/Sales Multiple

ImageneBio (IMA) - corporate logo

ImageneBio Inc focuses on destroying cancer cells by targeting their metabolism. The EV/Sales ratio confirms this strategy, with the parameter stabilizing at 0.00. The company's revenues are based on the implementation of targeted oncology therapies, although high research costs during the pre-profit period temporarily limit the overall business margins.

EV/Sales Multiple: Ikena Oncology, Inc. (IMA) for 11/23/2025 - 11/20/2026

Ikena Oncology, Inc. - analytical breakdowns and key metrics (IMA)

- market value and analyst target forecast:
Fundamental company valuation:ImageneBio - IMA
Finished products of ImageneBio

This indicator calculates the enterprise value including net debt divided by revenue, allowing for an assessment of the asset's real price without distortions from debt load. The current value of 0.00 reflects market optimism regarding the immuno-oncology prospects of ImageneBio Inc. (IMA), while the EV-to-sales multiple helps determine whether early-stage development risks are overvalued against the backdrop of venture financing.

Competitor analysis for ImageneBio Inc

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD